U.S., Dec. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07283770) titled 'Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy Participants' on Dec. 04.
Brief Summary: The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of single and multiple ascending doses of VX-581.
Study Start Date: Dec. 05
Study Type: INTERVENTIONAL
Condition:
Cystic Fibrosis
Intervention:
DRUG: VX-581
Suspension for Oral Administration.
DRUG: Placebo
Suspension for Oral Administration.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Vertex Pharmaceuticals Incorporated
Published by HT Digital Content Services with permission from Health Daily Digest....